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BACKGROUND
High rate of arterial and venous occlusive events were 
reported with ponatinib during clinical development1 and
serious cases of arterial occlusive disease were also 
reported with nilotinib.2 This led to the evaluation of the 
vascular safety profile of new generation BCR-ABL TKIs 
through a meta-analysis that confirmed the increased 
risk of vascular occlusive events with ponatinib and 
nilotinib compared with imatinib in chronic myeloid 
leukaemia (CML). The risk was also with dasatinib.3
However, distinction between arterial of venous events 
was not assessed.
1. Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC, et 
al. Rates of peripheral arterial occlusive disease in patients with chronic 
myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or 
non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 
2013;27(6):1310-5. 
2. Quintás-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated 
vascular events. Clinical lymphoma, myeloma & leukemia. 
2012;12(5):337-40.
3. Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogné JM. 
Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic 
Myeloid Leukemia and Cardiovascular Events, Major Molecular 
Response, and Overall Survival: A Systematic Review and Meta-
analysis. JAMA oncology. 2016.
• New generation TKIs increased risk of arterial and 
venous occlusive events compared with imatinib
• The increased risk of vascular occlusive events 
associated with new generation BCR-ABL TKIs is 
mainly driven by thrombotic events occurring at the 
arterial side.
• Additional investigations are required to assess the 
underlying pathophysiological mechanisms.
• Appropriate risk minimization measures should be 
taken/implemented with nilotinib, dasatinib and 
ponatinib.
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• Overall, 4.47% (99/2,217) of patients developed 
arterial occlusive events with new generation 
BCR-ABL TKIs compared with 0.80% (15/1,884) 
with imatinib (REM ORPETO: 3.46; 95%CI: 2.35 to 
5.10). 
• Venous occlusive events occurred in only 0.86% 
(13/2,217) of patients treated with new generation 
TKIs and in 0.16% (3/1,884) of imatinib-treated 
patients. 
Treatments
Venous occlusive events Arterial occlusive events
New generation 
TKIs
Imatinib
New generation 
TKIs
Imatinib
Bosutinib 0/248 (0.00) 0/251 (0.00) 3/248 (1.21) 1/251 (0.40)
Nilotinib 4/886 (0.45) 0/608 (0.00) 69/886 (7.79) 7/608 (1.15)
Dasatinib 8/929 (0.86) 3/873 (0.34) 16/929 (1.72) 4/873 (0.46)
Ponatinib 1/154 (0.65) 0/152 (0.00) 11/154 (7.14) 3/152 (1.97)
Overall 13/2217 (0.59) 3/1884 (0.16) 99/2217 (4.47) 15/1884 (0.80)
Table 1: Absolute risk of arterial and venous 
occlusive events in patients with CML.
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Scopus
187 articles
(148 articles)
The Cochrane 
database
128 articles
(95 articles)
Abstracts from 
congress
397 abstracts
(238 abstracts)
clinicaltrials.gov
489 trials
(270 trials)
Total abstracts for 
screening
N=770
(N=527)
First screening
N=407
(N=249)
Record excluded
N=348
Articles and 
abstracts eligible
N=59
(N=49)
23 articles (19)
36 abstracts (30) 
included for 
eligibility
18 articles and 35 abstracts 
excluded:
4 not in leukemic patients
22 updated data published
1 review
8 sub-analysis (5)
1 trial description
17 without pertinent data (8)
12 studies included for 
qualitative synthesis: (10)
•1 abstract (3)
•5 articles (6)
•6 clinicaltrials.gov (1) 
Trials meeting 
inclusion/exclusion 
criteria
N=21
(N=19)
9 studies excluded
 6 without results
 2 without vascular 
occlusive events
 1 without analysis
PubMed
58 articles
(46 articles)
12 studies included for 
quantitative synthesis: 
(10)
•1 abstract (3)
•5 articles (6)
•6 clinicaltrials.gov (1) 
Figure 1. PRISMA (Preferred Reporting Items for
Systematic review and Meta-Analysis) flow
diagram of study selection
• Twelve studies fulfilled the established criteria and 
were included in the meta-analysis. 
Figure 2: Forest plots of arterial and venous
occlusive events in patients with Ph+ CML treated
with new generation TKIs versus imatinib.
Arterial occlusive events
Venous occlusive events
• Ponatinib (REM ORPETO: 3.26; 95%CI: 1.12 to 9.50), 
nilotinib (REM ORPETO: 3.60; 95%CI: 2.21 to 5.86) and 
dasatinib (REM ORPETO: 3.32; 95%CI: 1.37 to 8.01) are 
associated with higher risk of arterial occlusive events 
than imatinib. 
• No significant difference was found with bosutinib but a 
trend indicate an increased risk of arterial occlusive 
events.
• Overall, new generation TKIs increase the rate of 
venous occlusive events (REM ORPETO: 2.85; 95%CI: 
1.04 to 7.78).
• Stratification by treatment for venous analysis 
demonstrates nonsignificant results due to the low 
power of the analysis.
Limitations
• Lack of time-to-event analyses
• Inconsistent report of cardiovascular events in the 
literature. 
• However, the use of a clinical trial register aimed to 
decrease this heterogeneity, and funnel plots 
demonstrate no evidences of publication bias. The I2
statistic specifies no heterogeneity among studies (data 
not shown).
OBJECTIVES
• To determine the risk of arterial and venous occlusive 
events in patients with Ph+ CML treated with new 
generation BCR-ABL TKIs in randomized clinical 
trials.
• Stratifications by treatment are performed to provide 
product specific risk assessment.
METHODS
Literature search
• Screening of scientific articles (PubMed, Scopus, 
Cochrane library), congress abstracts (ASH, ASCO, 
ESMO) and clinical trial register 
(www.clinicaltrials.gov)
• Selection of all randomized clinical trials comparing 
new generation TKIs versus imatinib in patients with 
Ph+ CML.
Data collection
• Study and population characteristics
• Arterial occlusive events
• Venous occlusive events
Statistical analysis
• Random- (REM) and fixed-effect models (FEM) have 
been used to analyze the risk of arterial occlusive 
events and venous occlusive events respectively.
• Effect size measure: odds ratio computing using 
Peto method
• Heterogeneity assessment: Cochran’s Q statistic and 
I2 value.
• One-way sensitivity analysis was performed to 
assess the robustness 
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